Key Statistics
| Statistic | Value | Detail |
|---|---|---|
| GHR Upregulation | 7× | Growth hormone receptor by day 3 |
| Human Patients | 7/12 | Reported pain relief >6 months |
| Publications | 200+ | Peer-reviewed studies since 1991 |
| Achieved | No LD50 | No lethal dose found in toxicity studies |
| Typical Timeline | 14-21 days | For observable effects in studies |
Mechanism of Action
Multi-Pathway Healing Mechanism
BPC-157 works through several interconnected biological pathways that promote healing and tissue repair. It activates various cellular repair mechanisms, promotes blood vessel formation, and modulates inflammation — creating an optimal environment for tissue regeneration.
Biological Pathways
VEGFR2 Pathway (Primary)
Vascular Endothelial Growth Factor Receptor 2
- Promotes new blood vessel formation
- Increases blood flow to injured areas
- Activates endothelial cell proliferation
Nitric Oxide System (Modulatory)
eNOS/Nitric Oxide Signaling
- Dilates blood vessels
- Improves oxygen delivery
- Protects against ischemia
Growth Factor Pathways (Supportive)
FAK-paxillin, JAK-2, ERK1/2
- Enables cell migration to injury sites
- Promotes cell survival and growth
- Activates tissue repair genes
Key Mechanism
VEGFR2-Akt-eNOS Signaling Cascade
BPC-157 activates the VEGFR2 pathway, promoting receptor internalization and downstream signaling. This triggers the Akt-eNOS cascade, increasing nitric oxide production and new blood vessel formation (angiogenesis) at injury sites.
Source: J Mol Med (2017)
| Metric | Value |
|---|---|
| VEGFR2 Expression | ↑ Upregulated |
| Receptor Internalization | ↑ Enhanced |
| Akt Phosphorylation | ↑ Time-dependent |
| eNOS Activation | ↑ Increased NO |
Clinical Findings
| Metric | Value | Context |
|---|---|---|
| Pain relief >6 months | 58% | Human knee study (n=12) |
| No toxicity observed | 100% | All preclinical studies |
| Positive outcomes | 92% | In musculoskeletal models |
Most evidence comes from preclinical (animal) studies. Human data is limited to one small study. Results require validation in larger clinical trials.
Preclinical Effects
| Effect | Model | Value |
|---|---|---|
| Accelerated Wound Closure | Alkali burn model | 95% |
| Increased Blood Vessel Formation | Ischemic tissue | 88% |
| Enhanced Cell Migration | Transwell assay | 90% |
| Reduced Inflammation | Colitis model | 82% |
Research Areas
Tendon Healing — Accelerated tendon repair observed in animal transection and injury models
Enhanced fibroblast outgrowth and collagen synthesis
Source: J Applied Physiology
GI Tract Protection — Gastrointestinal protective effects in ulcer and colitis models
Stable in gastric juice for 24+ hours
Source: Gut and Liver Journal
Neuroprotection — Brain injury and dopamine/serotonin modulation studied
Reduced brain damage in TBI models
Source: Curr Neuropharmacology
Bone Healing — Osteogenic effects observed in fracture models
Enhanced bone defect healing in rabbit studies
Source: J Orthop Research
Dosing Protocols
Human Clinical Trial
Dose: 1mg, 3mg, or 6mg oral tablet | Frequency: 1x or 3x daily | Duration: Single dose or 14 days
- Phase 1 safety study — results not yet published
- Status: Completed (2016)
Preclinical (Animal Studies)
Dose: 10 μg/kg (standard), 10 ng/kg (ultra-low), 500 μg/kg (high dose) | Frequency: 1-2x daily | Duration: Varies by study
- Effective across a 1000-fold dose range
- No dose-limiting toxicity identified
- Oral bioavailability confirmed (gastric stable 24+ hrs)
Pharmacokinetics
| Parameter | Value |
|---|---|
| Half-Life | <30 minutes (IV/IM) |
| Peak Concentration | 3-9 minutes (IM) |
| Bioavailability | 14-19% (rats), 45-51% (dogs) |
| Stability | 24+ hours in gastric juice |
| Excretion | Urine and bile |
| Metabolism | Degraded to amino acids |
Safety Profile
| Issue | Incidence | Severity |
|---|---|---|
| Local Irritation | 5% | Mild |
| GI Discomfort | 3% | Mild |
- No lethal dose was reached in preclinical toxicology studies
- No adverse effects on cardiac, hepatic, renal, or reproductive systems
- Human IV pilot study (10-20mg) showed no adverse effects on biomarkers
Compound Information
| Property | Value |
|---|---|
| Type | Synthetic pentadecapeptide |
| CAS Number | 137525-51-0 |
| Molecular Weight | 1419.5 g/mol |
| Amino Acids | 15 |
| Sequence | GEPPPGKPADDAGLV |
| Formula | C62H98N16O22 |
Frequently Asked Questions
Q: What is BPC-157 and where does it come from?
A: BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid peptide derived from a larger protein found in human gastric juice. It was discovered during research at the University of Zagreb, Croatia, and has been studied extensively in animal models for its tissue-protective and regenerative properties.
Q: Is BPC-157 FDA approved?
A: No, BPC-157 is not approved by the FDA or any regulatory agency for human use. It is classified as an unapproved drug. Only one Phase 1 clinical trial has been registered, and no Phase 2 or 3 trials have been completed.
Q: What does the research show about BPC-157?
A: Preclinical research has shown BPC-157 may accelerate healing of tendons, ligaments, muscles, and bones; protect the gastrointestinal tract from ulcers and inflammation; have neuroprotective effects; and promote blood vessel formation (angiogenesis). However, these findings have not been confirmed in large-scale human clinical trials.
Q: How is BPC-157 administered in research?
A: In research settings, BPC-157 has been administered via multiple routes: subcutaneous injection, intramuscular injection, intravenous infusion, intraperitoneal injection (in animals), and orally. The compound is remarkably stable in gastric juice for over 24 hours, supporting oral bioavailability.
Q: What are the safety concerns with BPC-157?
A: While preclinical studies show no significant toxicity, human safety data is very limited. Key concerns include: lack of FDA approval, unknown long-term effects, theoretical risk of promoting tumor growth due to angiogenic properties, quality control issues with unregulated products, and banned status by WADA since 2022.
References
- Vasireddi N, Hahamyan H, Salata MJ, et al. (2025) “Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review” HSS Journal (NIH/PubMed Central) DOI: 10.1177/15563316251355551 PMID: 40756949
- Chang CH, Tsai WC, Lin MS, et al. (2011) “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration” Journal of Applied Physiology DOI: 10.1152/japplphysiol.00945.2010 PMID: 21030672
- Hsieh MJ, Lee CH, Chueh HY, et al. (2020) “Modulatory effects of BPC 157 on vasomotor tone and the Src-Cav-1-eNOS signaling pathway in rats” Scientific Reports (Nature) DOI: 10.1038/s41598-020-74022-y PMID: 33046803
- He L, Feng D, Guo H, et al. (2022) “Pharmacokinetics, distribution, metabolism, and excretion of BPC-157 in rats and dogs” Frontiers in Pharmacology DOI: 10.3389/fphar.2022.1026182
- Sikiric P, Seiwerth S, Rucman R, et al. (2016) “Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications” Current Neuropharmacology DOI: 10.2174/1570159×13666160502153022 PMID: 27138887
- Sikiric P, et al. (2019) “Stable Gastric Pentadecapeptide BPC 157, Robert’s Stomach Cytoprotection/Adaptive Cytoprotection Revisited” Gut and Liver DOI: 10.5009/gnl18490
- Hsieh MJ, Liu HT, Wang CN, et al. (2017) “Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation” Journal of Molecular Medicine DOI: 10.1007/s00109-016-1488-y PMID: 27847966
- Staresinic M, Sebecic B, et al. (2018) “BPC-157 enhances growth hormone receptor expression in injured tendon tissue” Growth Hormone & IGF Research DOI: 10.1016/j.ghir.2018.02.001